Exicure Inc (XCUR) - Net Assets

Latest as of March 2026: $2.10 Million USD

Based on the latest financial reports, Exicure Inc (XCUR) has net assets worth $2.10 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.76 Million) and total liabilities ($10.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check XCUR tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets $2.10 Million
% of Total Assets 16.45%
Annual Growth Rate -14.23%
5-Year Change -65.05%
10-Year Change 60.38%
Growth Volatility 236.9

Exicure Inc - Net Assets Trend (2015–2025)

This chart illustrates how Exicure Inc's net assets have evolved over time, based on quarterly financial data. See Exicure Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Exicure Inc (2015–2025)

The table below shows the annual net assets of Exicure Inc from 2015 to 2025. For live valuation and market cap data, see Exicure Inc market capitalisation.

Year Net Assets Change
2025-12-31 $3.93 Million -42.03%
2024-12-31 $6.77 Million +123.42%
2023-12-31 $3.03 Million -79.69%
2022-12-31 $14.92 Million +32.85%
2021-12-31 $11.23 Million -81.74%
2020-12-31 $61.51 Million -23.83%
2019-12-31 $80.75 Million +285.39%
2018-12-31 $20.95 Million +4.89%
2017-12-31 $19.98 Million +715.97%
2016-12-31 $2.45 Million -86.57%
2015-12-31 $18.23 Million --

Equity Component Analysis

This analysis shows how different components contribute to Exicure Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 19854700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $1.00K 0.03%
Other Comprehensive Income $-2.00K -0.05%
Other Components $208.14 Million 5301.50%
Total Equity $3.93 Million 100.00%

Exicure Inc Competitors by Market Cap

The table below lists competitors of Exicure Inc ranked by their market capitalization.

Company Market Cap
Kps AG
XETRA:KSC
$13.71 Million
Skillful Craftsman Education Tech
NASDAQ:EDTK
$13.72 Million
Sambhaav Media Limited
NSE:SAMBHAAV
$13.72 Million
Iris Metals Ltd
AU:IR1
$13.72 Million
Capital Engineering Network Public Company Limited
BK:CEN
$13.70 Million
KSG Agro SA
WAR:KSG
$13.70 Million
Nafpaktos Textile Industry S.A
AT:NAYP
$13.70 Million
Atomos Ltd
AU:AMS
$13.69 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Exicure Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 6,772,000 to 3,926,000, a change of -2,846,000 (-42.0%).
  • Net loss of 4,946,000 reduced equity.
  • New share issuances of 1,600,000 increased equity.
  • Other comprehensive income decreased equity by 2,000.
  • Other factors increased equity by 502,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-4.95 Million -125.98%
Share Issuances $1.60 Million +40.75%
Other Comprehensive Income $-2.00K -0.05%
Other Changes $502.00K +12.79%
Total Change $- -42.03%

Book Value vs Market Value Analysis

This analysis compares Exicure Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.45x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 0.15x to 3.45x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2015-12-31 $13.92 $2.15 x
2016-12-31 $1.86 $2.15 x
2017-12-31 $15.19 $2.15 x
2018-12-31 $15.26 $2.15 x
2019-12-31 $42.00 $2.15 x
2020-12-31 $21.16 $2.15 x
2021-12-31 $3.80 $2.15 x
2022-12-31 $3.23 $2.15 x
2023-12-31 $0.38 $2.15 x
2024-12-31 $1.11 $2.15 x
2025-12-31 $0.62 $2.15 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Exicure Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -125.98%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 3.58x
  • Recent ROE (-125.98%) is above the historical average (-219.48%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2015 -72.14% -550.71% 0.12x 1.08x $-14.97 Million
2016 -692.03% -1635.23% 0.05x 8.41x $-17.19 Million
2017 -55.12% -113.29% 0.34x 1.45x $-13.01 Million
2018 -106.97% -18994.07% 0.00x 1.37x $-24.51 Million
2019 -32.57% -2029.55% 0.01x 1.43x $-34.38 Million
2020 -40.11% -148.49% 0.17x 1.63x $-30.82 Million
2021 -570.71% 0.00% -0.01x 5.78x $-65.23 Million
2022 -17.30% -8.96% 1.24x 1.56x $-4.07 Million
2023 -558.03% 0.00% 0.00x 3.82x $-17.22 Million
2024 -143.25% -1940.20% 0.03x 2.22x $-10.38 Million
2025 -125.98% 0.00% 0.00x 3.58x $-5.34 Million

Industry Comparison

This section compares Exicure Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $155,285,360
  • Average return on equity (ROE) among peers: -101.11%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Exicure Inc (XCUR) $2.10 Million -72.14% 5.08x $13.70 Million
Aardvark Therapeutics, Inc. Common Stock (AARD) $-34.80 Million 0.00% 0.00x $83.17 Million
Abcellera Biologics Inc (ABCL) $830.51 Million 14.32% 0.21x $1.61 Billion
Abeona Therapeutics Inc (ABEO) $-26.99 Million 0.00% 0.00x $321.39 Million
Acumen Pharmaceuticals Inc (ABOS) $266.97 Million -19.62% 0.16x $155.29 Million
Abpro Holdings, Inc. (ABP) $3.07 Million -479.81% 1.57x $2.00 Million
Absci Corp (ABSI) $179.13 Million -57.56% 0.19x $1.01 Billion
Arbutus Biopharma Corp (ABUS) $182.50 Million -46.25% 0.30x $831.63 Million
ABVC Biopharma Inc (ABVC) $4.59 Million -357.76% 1.38x $35.10 Million
Abivax SA American Depositary Shares (ABVX) $33.94 Million -14.97% 0.12x $7.98 Billion
ACADIA Pharmaceuticals Inc (ACAD) $113.93 Million -49.49% 0.18x $3.66 Billion

About Exicure Inc

NASDAQ:XCUR USA Biotechnology
Market Cap
$13.70 Million
Market Cap Rank
#26268 Global
#5421 in USA
Share Price
$2.15
Change (1 day)
-0.92%
52-Week Range
$2.15 - $8.86
All Time High
$975.00
About

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood Ci… Read more